Patents by Inventor Michael Coyle
Michael Coyle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250043315Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: July 23, 2024Publication date: February 6, 2025Applicant: LifeEDIT Therapeutics, Inc.Inventors: Gunjan H. Arya, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich, Joel S. Parker
-
Publication number: 20250027183Abstract: The present document related to the processing of mining materials, such as ores, rocks, minerals, and aggregate materials to separate valuable components. There is provided a process and system for extracting a valuable component from a mining feedstock comprising geological materials. The process can comprise subjecting the mining feedstock to a kinetic pulverization stage wherein the mining feedstock is subjected to self-collisions created by vortices within the kinetic pulverizer to produce a pulverized material; admixing the mining feedstock or the pulverized material with a chemical additive configured to selectively liberate the valuable component from the geological material; and subjecting the pulverized material to an extraction stage to produce a valuable component-rich stream and a valuable component-depleted stream.Type: ApplicationFiled: February 24, 2023Publication date: January 23, 2025Applicant: TORXX KINETIC PULVERIZER LIMITEDInventors: Christopher Mueller, Michael Drolet, Peter Everson, Terri Ward, Doulgas Coyle
-
Publication number: 20240401084Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: February 2, 2024Publication date: December 5, 2024Applicant: LifeEDIT Therapeutics, Inc.Inventors: Alexandra Briner Crawley, Rodolphe Barrangou, Tyson D. Bowen, Michael Coyle, Tedd D. Elich
-
Publication number: 20240376455Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: July 23, 2024Publication date: November 14, 2024Applicant: LifeEDIT Therapeutics, Inc.Inventors: Gunjan H. Arya, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich, Joel S. Parker
-
Publication number: 20240376456Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: July 23, 2024Publication date: November 14, 2024Applicant: LifeEDIT Therapeutics, Inc.Inventors: Gunjan H. Arya, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich, Joel S. Parker
-
Publication number: 20240294947Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: April 29, 2024Publication date: September 5, 2024Applicant: LifeEDIT Therapeutics, Inc.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
-
Publication number: 20240285264Abstract: An oral fluid sample collection device (“sampler”) for animals includes a member with an external layer that can be held in an animal's mouth, a recessed layer that encloses an absorbent test strip, and an aperture in the external layer, wherein oral fluids pass through the aperture to be in fluid contact with the test strip, while the recessed layer is not in direct physical contact with the animal's mouth. A sampler including a compressible external layer. A sampler including a carrying case with test strip enclosures attached, the carrying case inserted in the member. A sampler including an internal layer that supports test strips which everts when an animal's mouth applies pressure to the external layer.Type: ApplicationFiled: February 27, 2024Publication date: August 29, 2024Inventor: Brian Michael Coyle
-
Publication number: 20240189617Abstract: The present invention relates to devices, methods, and systems that emit light in the ruminant reticulorumen, to inactivate a distinct group of microbes. The device size and weight obtains a predetermined position in the rumen, and protectively contains a first power source, electric components, and light sources. The present invention contains methods of duty cycles and systems of second power sources to enable the first power source to operate the light sources for a prolonged period.Type: ApplicationFiled: September 1, 2023Publication date: June 13, 2024Inventor: Brian Michael Coyle
-
Patent number: 11981916Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: GrantFiled: September 1, 2022Date of Patent: May 14, 2024Assignee: LifeEDIT Therapeutics, Inc.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
-
Publication number: 20240130608Abstract: Controlled motion capsules and associated systems and methods are described. Controlled motion capsules can decelerate, and stop, without damaging epithelial walls. If any components fail, a controlled motion capsule, without added energy, becomes its most compact shape, passing harmlessly through the GI tract. Controlled motion capsule includes a stimuli-responsive hydrogel, comprising a reversible soft copolymer, in a compartment in the capsule, with an energy emitter, and a controller to variably activate energy emission to expand and contract the hydrogel, on detection of certain conditions or instructions. Hydrogel expansion is primarily described by an isotropic tensor, with any deviatoric strains aggregating to a minor degree. The spherically expanded hydrogel decelerates the controlled motion capsule through form drag, and may stop it through viscoelastic interaction with epithelial walls, which avoids damaging friction.Type: ApplicationFiled: December 11, 2023Publication date: April 25, 2024Inventor: Brian Michael Coyle
-
Patent number: 11926843Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: GrantFiled: September 17, 2021Date of Patent: March 12, 2024Assignee: LifeEDIT Therapeutics, Inc.Inventors: Alexandra Briner Crawley, Rodolphe Barrangou, Tyson D. Bowen, Michael Coyle, Tedd D. Elich
-
Patent number: 11883007Abstract: Controlled motion capsules and associated systems and methods are described. Controlled motion capsules can decelerate, and stop, without damaging epithelial walls. If any components fail, a controlled motion capsule, without added energy, becomes its most compact shape, passing harmlessly through the GI tract. Controlled motion capsule may include a shape changing material, comprising a reversible soft copolymer, in a container in the capsule, with a nonionizing radiation emitter, and a controller to activate the nonionizing radiation to expand and contract the shape changing material, on detection of certain conditions or instructions. Expansion of the shape changing material, including contact with epithelial walls, decelerates and can stop the controlled motion capsule movement. Motion control allows scientists to study the microbiome, doctors to deliver intestinal drugs at precise locations, and to closely examine signs of precancerous growth.Type: GrantFiled: May 26, 2022Date of Patent: January 30, 2024Inventor: Brian Michael Coyle
-
Publication number: 20240026384Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: August 10, 2023Publication date: January 25, 2024Applicant: LifeEDIT Therapeutics, Inc.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
-
Patent number: 11859181Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: GrantFiled: August 31, 2022Date of Patent: January 2, 2024Assignee: LIFEEDIT THERAPEUTICS, INC.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
-
Patent number: 11800851Abstract: The present invention relates to methods, systems, and devices that emit light energy in the ruminant rumenoreticulum, to inactivate a quantity of microbes. The device is a size or shape that will obtain a predetermined position within the rumenoreticulum, and protectively contains long lasting battery power, electric components, and light sources that emit wavelengths that inactivate and destroy microbes. The device, the system and the method according to the present invention also allow detection of biological parameters of the capsule environment and communication with a receiver outside the animal.Type: GrantFiled: December 29, 2019Date of Patent: October 31, 2023Inventor: Brian Michael Coyle
-
Publication number: 20230257742Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: August 31, 2022Publication date: August 17, 2023Applicant: LifeEDIT Therapeutics, Inc.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
-
Publication number: 20230248104Abstract: The present invention is a helmet system that reduces concussions by damping rotational force transmitted to a helmet user. The helmet has an helmet shell that moves independently from an internal body worn by the user. At least one magnetic force emitter on the helmet shell's interior directs at least one interior-facing magnetic flux axially at the internal body. At least one magnetic force emitter attached to the internal body directs at least one exterior-facing magnetic flux at the at least one interior-facing magnetic flux. In a resting state magnetic flux interactions are limited. When a tangential impact rotates the exterior shell, the at least one interior-facing magnetic flux approaches to the side of the at least one exterior-facing magnetic flux, inducing negative torque of the internal body in a variety of ways. Rotational momentum is diffused in a variety of ways. The exterior shell is returned to the resting state in a variety of ways.Type: ApplicationFiled: April 17, 2023Publication date: August 10, 2023Inventor: Brian Michael Coyle
-
Publication number: 20230235360Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: September 1, 2022Publication date: July 27, 2023Applicant: LifeEDIT Therapeutics, Inc.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
-
Publication number: 20230203463Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, detecting a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: December 28, 2020Publication date: June 29, 2023Applicant: LifeEDIT Therapeutics, Inc.Inventors: Alexandra Briner Crawley, Philip Borden, Tyson D. Bowen, Michael Coyle, Madison R. Rackear, Tedd D. Elich
-
Publication number: 20230175018Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: June 28, 2022Publication date: June 8, 2023Applicant: LifeEDIT Therapeutics, Inc.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich